WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical, Industry Outlook
Globenewswire | August 17, 2023
Mustang Bio Inc. a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-...
Cell and Gene Therapy
Puma Biotechnology | September 21, 2022
Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...
Evolugate | May 28, 2020
INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...
Cell and Gene Therapy, Diagnostics
Globenewswire | July 04, 2023
NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities.
The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University...
Cell and Gene Therapy, Industrial Impact
MedTech, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE